ArticleClinical and experimental medicine2020

LncPRYP4-3 serves as a novel diagnostic biomarker for dissecting subtypes of metabolic associated fatty liver disease by targeting RPS4Y2.

Hongju Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.